Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06076304
Other study ID # PLACER-2021C3-24476
Secondary ID 23-02-622
Status Active, not recruiting
Phase Phase 4
First received
Last updated
Start date November 21, 2023
Est. completion date May 2024

Study information

Verified date May 2024
Source Georgetown University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sinus infections are sometimes treated with antibiotics or nasal sprays, while some patients get better on their own. Some patients may wait a few days or use common over-the-counter remedies to see if their symptoms improve without further treatment. The overall goal of this clinical trial to see which patients with sinus infections are more likely to respond to different treatments, and which improve with supportive care alone.


Description:

One in seven adults are diagnosed with acute sinus infections (also known as rhinosinusitis or ARS) every year in the United States, for an annual total of 30 million office visits. Most acute sinus infections seen in outpatient setting are caused by viral infection, but antibiotics are prescribed in over 70% of these visits. The overarching goal is to improve outcomes for patients with ARS by understanding which subgroups are most likely to benefit from antibiotics, supportive care, watchful waiting, intranasal corticosteroids (INCS), or a combination of treatments. To assess the comparative effectiveness of the treatments, a large, pragmatic, randomized controlled trial, will be conducted in practice-based research networks within six geographical areas. Enrolled adults ages 18-65 years presenting to a clinician with symptoms consistent with ARS for less than 10 days will begin with a pre-randomization period with options for supportive care. Patients who reached more than 9 days of symptoms at the time of enrollment or during the waiting period will be randomly assigned to one of the four treatment arms. In preparation for the full-scale trial, a smaller feasibility study of the protocol will be piloted in a subset of clinics within the same research networks.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 144
Est. completion date May 2024
Est. primary completion date May 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: ? 18-65 years old; AND experiencing ongoing symptoms or signs that suggest an acute sinus infection lasting for 1-21 days, without any signs clinical improvement Exclusion Criteria: - allergy or intolerance to penicillin - received systemic antibiotic therapy in the past 4 weeks - prior sinus surgery - complications of sinusitis (facial edema (swelling), cellulitis), or orbital, meningeal or cerebral signs) - health care clinician determined IV (intravenous) antibiotics or hospital admission are required - pregnancy or breastfeeding - presence of a comorbidity or medication that may impair a patient's immune response as determined by a health care clinician - unable to read, speak or understand English or Spanish - hospitalization in past 5 days - unable or unwilling to provide informed consent or comply with study protocol requirements - fever >39°C or 102°F; OR - taking intranasal corticosteroids (INCS) regularly in the past two weeks

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Amoxicillin/clavulanate
Amoxicillin/clavulanate, oral, 875mg/125mg twice daily for 7 days
Placebo antibiotic
Placebo antibiotic, oral, twice daily for 7 days
Budesonide nasal spray
Budesonide nasal spray, 32 mcg per spray, 2 sprays per nostril, once per day
Other:
C-reactive protein
Measurement of C-reactive protein level in capillary blood
Mid-turbinate swab (optional)
Optional collection of mid-turbinate nasal swab sample

Locations

Country Name City State
United States Penn State College of Medicine Hershey Pennsylvania
United States MedStar Health Research Institute Hyattsville Maryland
United States University of California Los Angeles Los Angeles California
United States University of Wisconsin-Madison Madison Wisconsin
United States Virginia Commonwealth University Richmond Virginia
United States University of Washington Seattle Washington
United States Georgetown University Medical Center Washington District of Columbia

Sponsors (8)

Lead Sponsor Collaborator
Daniel Merenstein Medstar Health Research Institute, Patient-Centered Outcomes Research Institute, Penn State College of Medicine, University of California, Los Angeles, University of Washington, University of Wisconsin, Madison, Virginia Commonwealth University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Saline nasal irrigation Number of patients reporting use of saline nasal irrigation during the pre- and post-randomization study periods. Baseline to 14 days post-randomization
Other Watchful waiting Number of patients who experienced improvement or resolution of symptoms during the pre-randomization period (between enrollment and 9 days of symptoms). Baseline to 9 days of symptoms
Other Adherence Self-reported adherence to study pill and nasal spray are calculated by [number of doses taken]/[prescribed number of doses] x 100, over the 7-day intervention period. Days 1-7 post-randomization
Other C-reactive protein (CRP) Measurement of C-reactive protein (CRP) level in capillary blood Baseline
Primary Improvement of symptoms Improvement of symptoms will be assessed using the Modified Sino-Nasal Outcome Test (mSNOT-16), a disease-specific quality of life questionnaire. Sixteen sinus symptoms are self-assessed on a 0-3 point scale, with 0=No Problem, 1=Mild or Slight Problem, 2=Moderate Problem, 3=Severe Problem. Scores will be measured at baseline and 3 days post-randomization. Baseline and 3 days post-randomization
Secondary Improvement of symptoms Improvement of symptoms will be assessed using the Modified Sino-Nasal Outcome Test (mSNOT-16), a disease-specific quality of life questionnaire. Sixteen sinus symptoms are self-assessed on a 0-3 point scale, with 0=No Problem, 1=Mild or Slight Problem, 2=Moderate Problem, 3=Severe Problem. Scores will be measured at daily from baseline until 14 days post-randomization. Baseline to 14 days post-randomization
Secondary Work Productivity and Activity Impairment Questionnaire The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI: SHP) 2.0 is a 6-question self-reported questionnaire on the effects of sinus symptoms on the amount of absenteeism, presenteeism, work impairment, and daily activity impairment. WPAI will be assessed at baseline, 9 days of symptoms is reached, and 1, 7, and 14 days post-randomization. Baseline, 9 days of symptoms, and 1, 7, and 14 days post-randomization
Secondary Global Rating of Improvement Self-assessment of current sinus symptoms at each follow-up interview using a 6-point categorical scale (1=no symptoms, 2=a lot better, 3=a little better, 4=the same, 5=a little worse, or 6=a lot worse). Scores will be measured at baseline, when 9 days of symptoms is reached, and 3, 7, and 14 days post-randomization. Baseline, 9 days of symptoms, and 3, 7, and 14 days post-randomization
Secondary Symptomatic care Number of patients reporting use of over-the-counter medicines or supplements during the pre- and post-randomization study periods. Baseline to 14 days post-randomization
Secondary Adverse events Number of adverse events reported during a follow-up or on the diary during the the pre- and post-randomization study periods. Events are graded form 1-5 using the NCI Common Terminology Criteria for Adverse Events. Baseline to 14 days post-randomization
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05127161 - Broad Implementation of Outpatient Stewardship N/A
Completed NCT01700725 - Gulf War Illness Nasal Irrigation Study Phase 2
Completed NCT00552773 - Pilot Study to Determine Efficacy of Cyclamen Europaeum Extract Nasal Spray in Patients With Acute Sinusitis N/A
Completed NCT01806103 - Antimicrobial Stewardship for Primary Care Pediatricians N/A
Completed NCT02297815 - Comparative Effectiveness of Antibiotics for Respiratory Infections
Terminated NCT04664803 - Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis Phase 4